anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to a user interface method of a virus safety passport application for facility entry. There is an effect of preventing the spread of an infectious disease inside a facility, and simultaneously, when a person who has entered the facility has been determined to be an infected person, quickly specifying the other people who have entered in the same time zone in the same facility to give an alarm and take follow-up measures. To this end, the present invention proposes a user interface method for, when an entrant enters after a temperature check, authenticating an entry event and a facility. When the entrant&#39;s smartphone recognizes an NFC tag that stores a facility identification code, a user screen on which a virus safety passport application is to be installed is called. An entry authentication user screen is called by installing and then executing the virus safety passport application on the entrant&#39;s smartphone. When an input means presses an authentication request button on the entry authentication user screen, the mobile phone number of the entrant&#39;s smartphone is obtained by executing an SIM access module of the virus safety passport application, and then an authentication completion user screen is displayed while the facility identification code of the NFC tag and the entrant&#39;s mobile phone number are transmitted to a management server.
The coronavirus SARS-Cov-2 which started in Wuhan, China, in December 2019 induced a threat to global health. Patients with mental disorders were thought to be at increased risk of becoming infected for several reasons but very much to the inventors&#39; surprise, these psychiatric units remained nearly empty during the lock-down period as if psychiatric patients were protected from SARS-Cov-2 infection. Thus the inventors mined the literature to identify approved drugs with in vitro antiviral activities with a special emphasis on psychotropic drugs and compared these molecules using chemoinformatics strategies to the drugs most commonly used in their psychiatric department. A large number of compounds were found to be cationic amphiphilic drugs (CADs) and as such tend to also be phospholipidosis inducers in vitro (PLD). Several molecules most commonly used in their department were also found to have in vitro antiviral activity and/or can be clustered with compounds with known in vitro antiviral activity. Thus, drugs most commonly used for mental disorders with known in vitro antiviral activities are often CADs. In silico and in vitro analyses of these compounds together with the observations made in the department strongly suggest that commonly used psychotropic drugs and some related anti-histamine agents used as anxiolytics should protect psychiatric patients from SARS-Cov-2 infection.
NEW MATERIAL:A spiro compound shown by the formula I (R is H, or lower alkyl; X is group shown by the formula II, or formula III). EXAMPLE:Methyl 3-oxospiro[benzo[b]furan-2(3H),1&#39;-cyclopropane]-5-oxalate. USE:An antiulcer agent. Having an inhibitory action on secretion of acid in the stomach, preventing and remedying action on ulcer, effective for gastric ulcer, duodenal ulcer, acute and chronic gastritis, etc. PREPARATION:A compound shown by the formula IV is reacted with selenium dioxide, etc. in a mixed solvent of dioxane-water, etc. by heating under reflux to give an alpha-ketoaldehyde derivative shown by the formula V. It is then oxidized with manganese dioxide, etc. in an alcohol solvent in the presence of a catalyst (e.g., sodium cyanide, etc.) to give a compound shown by the formula I (R is lower alkyl, when X is group shown by the formula II).
PURPOSE:To provide the subject polypeptide exhibiting a human type caldesmon activity having a calmodulin affinity and an actin affinity, hopeful, e.g. for therapy of cancer, capable of being utilized for diagnosis of cancer and useful as a chimera protein or a transplantation material. CONSTITUTION:All the RNAs are extracted from Hela cells of human type cells by guanidine-cesium chloride method and a poly(A)&lt;+&gt;RNA is isolated by oligo(dT)-cellulose column chromatography. A cDNA is synthesized by using the isolated poly(A)&lt;+&gt;RNA as a template according to Gubler &amp; Hofmann method and a cDNA library is prepared by using the resultant cDNA according to the conventional method. The obtained cDNA library is inserted into a host colibacillus so as to form a plaque. Screening is carried out by a probe in which a chicken type caldesmon fragment is used so as to select a strain containing a gene coding human type caldesmon. The gene is recovered therefrom and a recombination gene is prepared so as to transform a host. The resultant transformat is cultured, thus affording the objective polypeptide represented by the formula and exhibiting human type caldesmon activity.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide brachytherapy in combination with an adjunctive therapy for the treatment of malignancy in solid organs.  &lt;P&gt;SOLUTION: An implantable cancer therapy device 14 includes adjacent segments 12 of a radioactive therapeutic element 16 and an adjunctive therapeutic element. The segments of radioactive therapeutic element and adjunctive therapeutic element can be alternatively disposed in a predetermined spatial array. The implantation can be permanent or temporary. The device can be a substantially cylindrical filament or a plurality of spaced radioactive seed overlaid with an adjunctive therapeutic element. The device 18 can also be a monofilament comprising an adjunctive therapeutic element, the monofilament having spaced depressions for indicating length and facilitating cutting.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject convenient dosage form comprising pseudoephedrine as a sustained release component and cetirizine as an immediate release component, capable of administering both the compounds as unit dosage forms so as to treat allergic rhinitis. SOLUTION: This dosage form is obtained by mixing (A) cetirizine of the formula as an immediate release component with (B) pseudoephedrine so that at least part of pseudoephedrine is contained in a core so as to continue the release of the part of the component B to a use environment. The dosage form is made not to contain an alcohol having a molecular weight smaller than 100 and its reactive derivative. Generally &gt;=80% of the component A is released within 1 hour after administration. Preferably, the component B is released for 8-24 days. The objective dosage form is obtained by coating a formed durable core containing the component B with an immediate release layer containing a water-soluble film-forming polymer. Preferably, the core is mixed with hydroxypropyl methyl cellulose and lactose.
Disclosed is a method of identifying genes whose gene products cause chromosome missegregation. The method involves transfecting a mammalian gene being assessed into a cell and then assessing whether the progeny cells have increased aneuploidy or increased chromosome breaks or translocations compared with cells that have not been transfected with the gene. Genes identified in this manner are likely to be involved in causing diseases such as cancer and Alzheimer&#39;s Disease, which result from improper chromosome segregation. Also disclosed is a method of identifying agents which can be used in the treatment of diseases caused by improper chromosome segregation. The method involves treating cells that have been transfected with a gene whose gene product causes improper chromosome segregation with an agent being assessed. Cells showing less aneuploidy or less chromosomal breakage or translocation compared with untreated cells indicate that the agent is useful in the treatment of diseases caused by improper chromosome segregation.
Thiosemicarbazones of chalcones, of general formula &lt;FORM:0692060/IV (b)/1&gt; where R=aryl, substituted or not; R1=alkyl, substituted or not; R11=hydrogen or alkyl, substituted or not; are prepared by the action of thiosemicarbazide upon a chalcone.  The thiosemicarbazone of benzalacetone is prepared by adding a saturated aqueous solution of thiosemicarbazide at 90 DEG  C. to a saturated solution of benzalacetone in alcohol at 60-70 DEG  C. and heating on a steam bath.  The thiosemicarbazones of salicylalacetone, 6-hydroxy-3-methyl benzalacetone and 4-acetamino-benzalacetone are prepared by similar methods.ALSO:A composition adapted for combating microorganisms of the genus Brucella comprises at least one active hydrophil component which is capable of substantially reducing the growth of Brucella in a hydrophilic medium and at least one active lipophil component which is capable of substantially reducing the growth of Brucella in a lipoidic medium.  Specified hydrophil components are: - antibiotics e.g. aureomycin, streptomycin, chloromycetin and patulin; sulpha compounds e.g. sulphadiazine and p-phenylsulphanilamide; 1,4-hydroquinone; a -naphthoquinone; and 3-methyl a -naphthoquinone. Typical lipophil components are the chloro-, bromo-, nitro- or acyl derivatives of 1,4-hydroquinone e.g. 2-bromo-, 2-chloro-, 2,5-dibromo-, 2,5-dichloroderivatives and quinacetophenone; the thiosemicarbazones of patulin; the semicarbazones of patulin; and the thiosemicarbazones of chalcones of general formula:- &lt;FORM:0692060/VI/1&gt; where R=aryl, substituted or not; R1=alkyl, substituted or not; R11=hydrogen or alkyl, substituted or not. Examples are the thiosemicarbazones of benzalacetone, 6-hydroxy-3-methylbenzal acetone, salicylalacetone, 4-acetamino benzalacetone and 3-nitrobenzalacetone.  Substances promoting the growth of lactobacillus e.g. galactose, lactose, glucose or stabilised lactobacilli may be added to the compositions, especially those in the form of vaginal pencils and suppositories. Examples are given of vaginal pencils containing 1,4-hydroquinone and 2-bromo-1,4-hydroquinone; lactose, galactose, glucose or stabilised lactobacilli; polymerised ethylene oxide; as such, or with the further addition of one or more of the following: thiosemicarbazone or semicarbazone of patulin, starch, paraffin wax, glycerin and gelatin.  An ointment has a base of petroleum jelly, liquid paraffin, lanolin, emulsifier and water.  Oral preparations consist of the active components and galactose, or lactose or a phosphate buffer. Pastils may have magnesium stearate as excipient.  The compositions may be administered to both man and animals by injection, orally, rectally or vaginally. Aqueous emulsions of vegetable or mineral oils may be used for general application to stables and the like.  The thiosemicarbazone of patulin is described in Specification 679,391, [Group IV (b)].  The thiosemicarbazones of chalcones of the above formula are prepared by the action of thiosemicarbazide upon a chalcone (see Group IV (b)).
FIELD: medicine. SUBSTANCE: the distinguishing feature of disclosed medicinal starvation method lies in limiting the consumption of liquid for which purpose the &#34;dry&#34; fasting periods are alternated with periods when patients drink only fresh spring water, only for quenching thirst. Consumption of fresh-made juices and raw-food in initial and final periods of starvation is limited only by appetite. To facilitate tolerance for fasting with total abstention from liquid, the patients are prescribed baths and aquatic procedures. EFFECT: improved tolerance for medicinal starvation, diminished feeling of hunger, possibility to fast under habitual conditions while retaining working capacity. 2 cl
Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient&#39;s hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient&#39;s T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin). After this, a donor-derived allogeneic stem cell preparation is administered to the patient. Patients treated according to the claimed invention develop donor-specific unresponsiveness and relatively fewer complications as compared to standard M/L conditioning regimens. The claimed methodologies should prove useful in the treatment of a number of hematologic malignancies such as chronic myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia, and non-Hodgkin&#39;s lymphoma.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a pharmaceutical formulation that directly and efficiently delivers a nucleic acid compound such as nucleic acid, gene, etc., to the disease part of an intractable pulmonary diseases such as lung cancer, pulmonary fibrosis, etc., by using a nanoparticle, effectively and continuously develops actions and has high safety.  &lt;P&gt;SOLUTION: The pharmaceutical formulation for transpulmonary administration comprises nanoparticles obtained by sealing a nucleic acid compound such as plasmid, siRNA, etc., acting on target molecules in intractable pulmonary diseases such as lung damage/pulmonary fibrosis, lung cancer, bronchial asthma, etc., in a biocompatible polymer. Consequently, the nucleic acid compound is efficiently introduced organ specifically and disease site specifically into the body. Actions are continuously developed by gradual release of the nucleic acid compound from the insides of the nanoparticles. Possibility to clinical applications is increased due to minimization of influence on the whole body.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention relates to a novel use of CMTR1 having siRNA production and function enhancement activity. Specifically, the present invention relates to a composition for enhancing the production of siRNA, comprising CMTR1 (cap1 2&#39;-O-ribose methyltransferase) protein as an active ingredient, and a composition for enhancing gene silencing activity by siRNA. The present invention also relates to a method for producing siRNA for gene silencing in vitro. CMTR1 according to the present invention can enhance the production of siRNA for gene silencing and, at the same time, promote the formation of a holo-RISC (RNA-induced silencing complex) that acts on the silencing of a target gene in the RNAi mechanism. The present invention has the effect of enhancing the production and function of siRNA without modification. Therefore, when CMTR1 of the present invention is used, the same can be usefully used in the development of pharmaceuticals using siRNA as a therapeutic agent.
The invention discloses a new application of 3&#39;UTR of JAM-A. The JAM-A3&#39;UTRoeDPC is obtained by successfully constructing an expression plasmid of the 3&#39;UTR of JAM-A and performing human dermal papilla cell (DPC) plasmid transfection. Compared with the DPC, the JAM-A3&#39;UTRoeDPC can keep the primitiveness of the papilla in vitro for a long time and can express the specific marked molecules of DPC on a high level, such as versican and ALPL after growth of agglomeration samples thereof for multiple generations. Each group of the cell is transported to the three-week-old nude mice skin tissue, and the conditions that the nude mice hair growth can be obviously promoted and the new hair can be thickened compared with the matched group by using the plasmid transfected DPC are found. A new concept and mode can be provided for culturing the human dermal papilla cell in vitro, maintaining and recovering the primitiveness of the DPC cell. A new concept and method for transplanting the DPC to induce the hair regeneration also can be increased.
PROBLEM TO BE SOLVED: To produce an improved cosmetic and a drug preparation for individual use by using a new silicone-ester wax having at least one specific ester part as a substitute for various natural waxes. SOLUTION: This cosmetic contains a silicone-ester wax expressed by formula I (R is H or an organic group; R&lt;1&gt; is &gt;=12C ester-containing group; (a) is 0-3; (b) is 0-3; the average of a+b is a value to give an essentially liner siloxane chain; R&lt;1&gt; is a group derived from a carboxylic acid having an olefinic unsaturated group on the terminal and an alcohol, etc.) and has a melting point of 40-90 deg.C. The R&lt;1&gt; of the wax is especially preferably the group of formula II ((x) and (y) are each an integer of &gt;=4). Preferably, the carboxylic acid is undecylenic acid and the alcohol is stearyl alcohol. The group R&lt;1&gt; is especially preferably derived from trimethylolpropane monoallyl ether and stearic acid. The wax is used as a stick cosmetic such as lipstick, bronze, rouge and eye shadow.
PURPOSE:To provide the title new gene to be used for mass production, by the genetic engineering technique, in high purity, of guinea pig MBP to be used for studying, elucidating, etc., the morbid states of allergic diseases. CONSTITUTION:The objective gene containing a DNA base sequence, e.g. a base sequence of the formula. Using poly(A) RNA screened from the whole RNA in the eosinophilic leukocytes of purified guinea pig MBP, CDNA is synthesized by the Gubler &amp; Hoffmann technique, being amplified in Escherichia coli, thus constructing a CDNA library. For amplifying part of the CDNA synthesized, the CDNA for probe for MBP screening is put to amplificative synthesis with a mixed primer through the PCR process according to the Kawasaki &amp; Wong technique followed by connection to PUC 118 plasmid and labeling the CDNA portion with [alpha-&lt;32&gt;P]dCTP. With the product as a screening probe, positive clone selected from the CDNA library is purified, thus obtaining the aimed CDNA.
1346535 Diphenylamines L&#39;OREAL 13 July 1972 [14 July 1971] 32815/72 Heading C4P [Also in Division D1] The invention comprises diphenylamines of the general formula wherein each of R 1  and R 2  are H 1  halogen of C 1 -C 4  alkyl, at least one of R 1  and R 2  being other than H, each of R 3 , R 4 , R 5 , R 6  and R 7  is H or C 1 -C 4  alkyl optionally substituted by one or more OH, carbamoyl, piperidinyl or acylamino groups, or R 3  and R 6  or R 4  and R 7  together with the linking carbon and nitrogen atoms complete dihydrooxazinyl or pyrrolinyl rings, and 2 is an amino, acylamino or OH group, and their salts with organic and inorganic acids, e.g. hydrochlorides, oxalates and tartrates. They are prepared by (a) reducing the corresponding indoaniline in an aqueous alkaline medium with a reducing agent, e.g. sodium hydrosulphite or ammonium sulphide or in an organic solvent, e.g. an alcohol by catalytic hydrogenation using palladium or barium sulphate or on charcoal or (b) by condensing a dinitro compound of general formula with a p-aminophenol substituted by R 1  and R 2  and then reducing the dinitro diphenylamine formed. The dyes are used to dye hair.
The invention comprises bases of the formula &lt;FORM:0980003/C2/1&gt; and quaternary derivatives thereof of the formula &lt;FORM:0980003/C2/2&gt; wherein R represents a C9- 17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1- 4 alkyl group or a C1- 4 hydroxyalky group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine, or pyrrolidine group; R3 represents a C1- 4 alkyl group, a C1- 4 hydroxy-alkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate. The bases are prepared by reacting together substantially equimolecular proportions of an alkali metal salt of a carboxylic acid of the formula R.COOH with an epihalohydrin and a secondary amine of the formula HNR1R2 in a solvent medium, and separating of the alkali metal halide formed simultaneously.  The quaternary compounds are prepared by quaternating the corresponding base with a compound R3X.ALSO:A liquid shampoo composition contains 0.5 to 10% by weight of a quaternary compound of the formula &lt;FORM:0980003/C4-C5/1&gt; wherein R represents a C9- 17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1- 4 alkyl or C1- 4 hydroxyalkyl group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine or pyrrolidine group; R3 represents a C1- 4 alkyl group, a C1- 4 hydroxyalkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate. Optional ingredients specified are lauryl alcohol ethylene oxide condensate, lauryl imidazoline quaternized with monochloracetic acid, water and lactic acid.ALSO:An anti-scurf lotion comprises an aqueous ethanol solution of a quaternary compound of the formula &lt;FORM:0980003/A5-A6/1&gt; wherein R represents a C9-17 aliphatic hydrocarbon group; R1 and R2 independently represent a C1-4 alkyl or C1-4 hydroxyalkyl group, or taken together with the nitrogen atom to which they are attached represent a morpholine, piperidine or pyrrolidine group; R3 represents a C1-4 alkyl group, a C1-4 hydroxyalkyl group or an araliphatic group; and X represents an anion, e.g. halide or methosulphate.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a soybean extract having more protein (≥40 % in a solid) than regular broth, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The soybean extract is obtained by hot water extraction of soybeans which is gradually subjected to hot water treatment and single-cell forming treatment. The soybeans to be used are dehulled soybeans. The hot water treatment comprises steaming the soybeans in hot water at 100-150°C for 5-60 min. The single-cell forming treatment comprises substantially forming the cells of the soybeans into single cells by physical treatment. The method for producing the soybean extract comprises subjecting the soybeans to hot water treatment followed by physical treatment to form into single cells, and subjecting the soybeans to hot water extraction in order to obtain the extract having more protein (≥40 % in a solid) than regular broth. An inhibitor of angiotensin converting enzyme comprising either one of the soybean extracts is also provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
FIELD: biotechnology, plant selection. SUBSTANCE: cystatinous proteinase inhibitor (orisacystatine 1) which reveals a deletion of aspartic acid in position 86, and a hybrid proteinase inhibitor including cystatine and proteinase inhibitor are used to fight pathogens, parasites and pests. Body transformation by DNA molecule coding proteinase inhibitors makes it to be resistant to proteolytic splitting. Proteinases&#39; inhibitors could be, also, obtained by using the primers. EFFECT: higher efficiency in selection of organisms, for example, plants. 18 cl, 8 dwg
A solution adapted for parenteral administration to reduce the duration of vasoconstrictorpotentiated local anaesthesia comprises as essential ingredients an aminomethylbenzodioxan, adenosine and water. The aminomethylbenzodioxans specified are 2-substituted-1 : 4-benzodioxan derivatives of formula &lt;FORM:0797237/VI/1&gt; where -N=B, is a tertiary amine grouping, e.g. piperidino, morpholino or diethylamino, and are generally used in the form of the acid addition salts, e.g. hydrochloride.  The piperidino compound, also known as &#34;piperoxan,&#34; is preferred.  The adenosine may be used in the form of the adenine-riboside, or as the mono- or triphosphate esters.  The solutions should also be isotonic and sufficient sodium chloride is incorporated for that purpose, and various other compounds such as buffering agents are added to produce a pH of between 3.5 and 7.  The preferred compositions according to the invention contain 0.01 to 0.5 per cent w./v. of piperoxan, 0.1 to 0.3 per cent w./v. of adenosine and enough sodium chloride to make the solution isotonic.